How to Help Your Patients Find Depo-Provera in Stock: A Provider's Guide

When a patient calls to say they can't find Depo-Provera at their pharmacy, the clock is already ticking. Depo-Provera's 13-week effectiveness window means that delays in accessing the injection carry real consequences for contraceptive protection. This guide gives you a practical framework for helping patients navigate access challenges quickly and effectively.

Step 1: Triage the Urgency

The first question to answer is: how much time does the patient have?

>2 weeks until the 13-week window closes: Low urgency. Help the patient find stock in the next 7–10 days using the tools below.

Within the final week of the window: High urgency. Prioritize same-day or next-day injection. Consider walk-in clinics, Title X sites, or your own office.

Past the 13-week window: Requires pregnancy test before re-injection. Advise backup contraception for 7 days after the late injection. Document this in the chart.

Step 2: Use Tools to Check Real-Time Availability

medfinder for Providers checks pharmacy stock near your practice or near your patient's location. Your staff can initiate a search on behalf of a patient—it contacts pharmacies directly and returns results by text, eliminating the need for extended phone tag. This is particularly useful for:

Patients in rural areas where only a few pharmacies serve a large region

Patients who have already called multiple pharmacies without success

Busy clinical practices where staff time for pharmacy calls is limited

Step 3: Know the Stocking Landscape in Your Area

Keep a short list of consistent supply sources for Depo-Provera in your area:

Your own clinic inventory: If your practice administers injections in-house, maintain a buffer stock of 2–4 weeks. Order proactively before inventory drops below 2 vials/syringes.

Planned Parenthood and Title X clinics: These federally funded sites maintain consistent DMPA supply. Build a referral relationship with your local center for patients who can't access your office in time.

Hospital-based OB/GYN clinics: Usually maintain clinical supply and may accept walk-in injection requests.

Health department family planning programs: Many county health departments offer contraceptive injections on a sliding-scale basis.

Step 4: Clarify Generic vs. Brand

When writing or sending the prescription, specify "medroxyprogesterone acetate injectable suspension, 150 mg/mL" and allow generic substitution. Some pharmacies stock only the generic (Prasco/Pfizer generic) and not the brand-name Depo-Provera. They are therapeutically identical—ensuring your prescription doesn't specify brand only can dramatically widen the supply pool available to your patient.

Step 5: Discuss Depo-SubQ Provera 104 as an Access Solution

For patients with reliable access to the internet and the dexterity to self-inject, Depo-SubQ Provera 104 (104 mg/0.65 mL subcutaneous injection) can be a practical solution. After initial clinical training, patients can administer this formulation at home, eliminating the need to schedule a clinical visit every 13 weeks. It is also FDA-approved for endometriosis-associated pain management.

Important: The December 2025 meningioma warning applies to Depo-SubQ Provera 104 as well. Counsel patients accordingly.

Step 6: Consider Whether This Is an Opportunity to Reassess the Method

Each access difficulty is an opportunity for a brief contraceptive counseling conversation. If a patient has been on Depo-Provera for more than 2 years, is experiencing difficulty accessing injections, or is concerned about the meningioma risk, this is an ideal time to discuss long-acting reversible contraceptives (LARCs) like Nexplanon or IUDs.

LARCs offer:

Higher typical-use effectiveness (>99%)

No access issues once placed

No meningioma or bone density concerns (hormonal IUDs and implant)

Longer duration of action (3–10+ years)

Documentation Tip

Document in the patient's chart: date of last injection, counseling provided regarding meningioma risk, and any steps taken to assist with access. If the patient received a late injection, note that a pregnancy test was performed and that backup contraception was advised. For the clinical background on the 2026 label change, see our provider shortage and label update guide.